basiliximab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
basiliximab

GtoPdb Ligand ID: 6879

Synonyms: CHI-621 | L04AC02 | SDZ-CHI-621 | Simulect®

basiliximab is an approved drug (FDA (1998), EMA (1998))

Compound class: Antibody

Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

View more information in the IUPHAR Pharmacology Education Project: basiliximab

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Amlot PL, Akbar AN, Heinrich G, Cammisuli S. (2002) Methods Of Treatment Using Cd25 Binding Molecules. Patent number: US6383487. Assignee: Novartis Ag, University College London. Priority date: 16/03/1990. Publication date: 07/05/2002.

References

1. Amlot PL, Akbar AN, Heinrich G, Cammisuli S. (2002)
Methods Of Treatment Using Cd25 Binding Molecules.
Patent number: US6383487. Assignee: Novartis Ag, University College London. Priority date: 16/03/1990. Publication date: 07/05/2002.